LymphomaArchives
TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma
Lymphoma 1 min.
Although CAR-T cell therapy has emerged as a promising therapeutic option for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), long manufacturing time, high cost and toxicities limit its clinical use. T-cell engagers (TCEs) including glofitamab may address these unmet needs, but real-world...
Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library
Lymphoma 1 min.
Three patient-reported outcome (PRO) measures specific to lymphoma symptoms were previously defined using mixed-methods research, comprising questions from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) and Item Library (IL):...
Epstein-Barr virus-associated lymphoma: current understanding and treatment strategies
Lymphoma 1 min.
Epstein-Barr virus (EBV) infection is well-known for its high prevalence rate, association with several diseases including cancer and autoimmune conditions, and a wide variety of symptoms and prognosis. When acquired at a young age, primary infections are often asymptomatic; however, in adolescence and...
Utility of various positron emission tomography tracers in differentiating primary central nervous system lymphoma from glioblastoma multiforme
Lymphoma 1 min.
Primary central nervous system lymphoma (PCNSL) can be differentiated from glioblastoma multiforme (GBM) using positron emission tomography (PET) with [F]fluoro-2-deoxy-D-glucose (FDG). However, differentiation is often difficult with magnetic resonance imaging (MRI) or FDG PET alone. We have used various...
